Conclusion
hypoalbuminemia, edema
HYPOALBUMINEMIA, EDEMA, PANCREATIC DUCTAL ADENOCARCINOMA
In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.This article evaluates the safety profile and clinical efficacy of ficlatuzumab (AV-299), in combination with standard systemic chemotherapy of gemcitabine and albumin-bound paclitaxel, in patients with metastatic pancreatic ductal adenocarcinoma.